According to a new market research report published by Global Market Estimates, the Global Plasmid DNA Manufacturing Market is projected to grow at a CAGR value of 24.5% from 2022 to 2027. The global plasmid DNA manufacturing market is expected to proliferate due to the rising demand for plasmid DNA in various medical therapies, increasingly successful clinical outcomes of using plasmid DNA in medical procedures, the growing prevalence of people suffering from multiple diseases and rapid growth advancements in the biopharmaceutical industry.

Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Plasmid DNA Manufacturing Market - Forecast to 2027" https://www.globalmarketestimates.com/market-report/plasmid-dna-manufacturing-market-3762

 Key Market Insights

·         As per the end-use scope outlook, the pharmaceutical and biopharmaceutical companies’ segment is expected to grow the fastest in the market from 2022 to 2027.

·         The cell and gene therapy manufacturing segment are expected to be the largest segment in the market from 2022 to 2027 as per the application segmentation

·         The cell and gene therapy manufacturing segment is expected to be the largest segment in the market from 2022 to 2027.

·         North America (the United States, Canada, and Mexico) will have a dominant share in the Global Plasmid DNA Manufacturing market from 2022 to 2027

·         Thermo Fisher Scientific, Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Charles River Laboratories, Aidevron, Sartorius AG, Kaneka Eurogentec S.A., Catalent, Inc., Vigene Biosciences, Creative Biogene and VGXI, Inc. among others are the key players in the plasmid DNA manufacturing market.

Step Scope Outlook (Revenue, USD Billion, 2022 - 2027)

·         Process Development

·         cGMP manufacturing

·         QC and Analytical

·         Others

Scale Outlook (Revenue, USD Billion, 2022 - 2027)

·         Research-Grade Plasmid

·         Industrial Grade

·         Others

Application Scope Outlook (Revenue, USD Billion, 2022-2027)

·         Cell & Gene Therapy Manufacturing

·         Vaccines Development

·         Viral Vector Manufacturing

·         Research Applications

End-use Scope Outlook (Revenue, USD Billion, 2022-2027)

·         Pharmaceutical and Biopharmaceutical Companies

·         Government & Academic Research Institutes

Regional Outlook (Revenue, USD Billion, 2022-2027)

North America                                                                                 

• The U.S.
• Canada
• Mexico

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC

Central & South America

• Brazil
• Argentina
• Rest of CSA

Middle East & Africa

• Saudi Arabia
• UAE
• Rest of MEA

 

Contact: Yash Jain

Email address: yash.jain@globalmarketestimates.com

Phone Number: +16026667238